Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · MetaVia Inc. (MTVA)

MetaVia appoints Sarah Browne, M.D. as Chief Medical Officer, effective October 12, 2026

Neutral Impact 3 of 5 leadership Written later

MetaVia Inc. named Sarah Browne, M.D. as its Chief Medical Officer, effective October 12, 2026, as disclosed in an 8-K filed October 13, 2026. The company said she will support development of DA-1726 ahead of an anticipated fourth quarter 2026 topline data readout from Part 3 of a Phase 1 trial.

Key points

  • Appointment effective October 12, 2026; announced in a press release dated October 13, 2026
  • Dr. Browne previously led clinical development of pemvidutide at Altimmune, Inc., through Phase 2
  • Company expects topline data from Part 3 of the Phase 1 DA-1726 trial, testing 48 mg and 64 mg doses, in Q4 2026

The filing

CompanyMetaVia Inc. (MTVA)
Form8-K, current report
Filed with the SECOct 13, 2026, 8:35 AM ET
Accession number0001104659-26-115300

Items reported: 7.01 Regulation FD Disclosure8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 13, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.